You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. New heterocyclic inhibitors of filoviruses

    SBC: MICROBIOTIX, INC.            Topic: H

    DESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Nitric Oxide Microfluidic Sensor

    SBC: CLINICAL SENSORS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant This Small Business Innovation Research SBIR Phase I project aims to develop a microfluidic based nitric oxide NO sensor as an early sepsis risk assessment device Sepsis causes significant strain on the U S healthcare system consuming over $ billion annually due to extended hospital stays and significant morbidity and mortality Rapid diagnosis and in ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. New small molecule inhibitors of arenaviruses

    SBC: MICROBIOTIX, INC.            Topic: R

    DESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Rabbit InMAD Discovery of Novel Biomarkers for POC Tuberculosis Diagnostic Assay

    SBC: Immuno-mycologics, Inc.            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is a chronic infectious disease that infects approximately one third of the worldandapos s population Eighty five percent of the estimated million new cases of TB in occurred in resource limited countries located in Asia and Africa In there were million deaths from TB among HIV negative patients and additional TB d ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel commensal polysaccharide treats multiple sclerosis through Treg modulation

    SBC: SYMBIOTIX BIOTHERAPIES, INC.            Topic: NIAID

    Abstract Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease that is the most common neurological disease of young adults, affecting over 350,000 patients in the US and over 2.5 million patients worldwide. MS is a disease of high unmetmedical need, currently treatable with one of several approved drugs, all of which result in either immune modulation or significant immunosuppre ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease

    SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC.            Topic: NIA

    Abstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Picture Me Fit: Engaging Youth in Community-Based Prevention

    SBC: Prevention Strategies, LLC            Topic: 600

    DESCRIPTION provided by applicant Approximately one third of all U S adults and children are obese and at risk for a wide range of related chronic health conditions such as cardiovascular disease hypertension diabetes stroke osteoarthritis sleep apnea and certain types of cancer The Center for Disease Control and Prevention CDC and other expert resources recognize that although indivi ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cyto

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Polychromatic flow cytometry [FC] is one of the most powerful analytical techniques routinely used in immunology. Flow cytometry plays a critical role in several growing clinical applications: leukemia and lymphoma immunophenotyping for diagnosis and sub-categorization (now using 8-10 colors); in CD4/CD8 measurement in HIV-positive patients; and in HLA typing f ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. DNP Polarization Agents for Real-Time Metabolic Imaging and Clinical Diagnosis

    SBC: DYNUPOL, INC.            Topic: NCI

    Project Summary / Abstract Although standard MRI techniques provide valuable structural insight, a related technique known as magnetic resonance spectroscopy (MRS) adds powerful real-time metabolic information about the tissues under study. MRS provides early detection of disease, monitoring treatment efficacy, and, in the case of cancer, a dramatic reduction in unnecessary biopsies. However, bro ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. F10: a novel therapeutic to treat refractory or relapsed AML

    SBC: SOUTHEAST TECH INVENTURES            Topic: NCI

    DESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government